Skip to main content
. 2018 May 16;8(2):291–301. doi: 10.1007/s13555-018-0240-7

Fig. 1.

Fig. 1

UAS7 of patients treated with the first cycle of omalizumab. Complete (UAS7 = 0) and good responders (1 ≤ UAS7 ≤ 6) are indicated by continuous lines, partial responders (6 < UAS7 < UAS7 at baseline) by short-dashed lines, and non-responders (UAS7 ≥ UAS7 at baseline) by long-dashed lines